Modern concepts of erythematotelangiectatic rosacea pathogenesis and treatment

Abstract

Rosacea is a multifactorial chronic pathology characterized by a complex etiopathogenesis. Rosacea is represented by 4 subtypes: erythematotelangiectatic, papulopustular, rhinophyma and ophthalmic rosacea.

Clinical manifestations of erythematotelangiectatic rosacea reduce the quality of human life, which is manifested by disorders of the psychoemotional sphere of varying severity. The erythematotelangiectatic subtype is influenced by two groups of trigger factors ― internal and external.

Mandatory areas of patients management with rosacea in general include the “triad of treatment”: providing proper skin care, health education, a set of therapeutic measures.

Rosacea drug therapy is divided into local and systemic. The main treatment for erythematotelangiectatic rosacea is to eliminate the vascular component and reduce the severity of transient and persistent erythema.

Among the physiotherapeutic methods, the most promising today are considered to be laser therapy and an intense pulsed light system (IPL). The effectiveness of laser medicine in dermatology is due to the ability to selectively build up the laser of the chromophochic layer of the dermis. The mechanism of action of IPL-therapy is associated with the absorption of photons by internal or external chromophores, which are located in different layers of the skin, which can locally increase the temperature and cause destructed target formations.

A review of the literature on pathogenesis, trigger factors, classification and modern treatment of eerythematotelangiectatic rosacea is based on an analysis of articles on the relevant topic 44 presented in information systems electronic library, PubMed, NCBI, Embase. Studies are described demonstrating the convincing effectiveness of the treatment of patients with lasers and the IPL system.

Keywords

skin / rosacea / teleangectasia / topical therapy / broadband pulse light / IPL-therapy / brimonidine / 0.5% brimonidine gel tartrate

References

[1] Rainer BM, Fischer AH, Luz Felipe da Silva D, et al. Rosacea is associated with chronic systemic diseases in a skin severity-dependent manner: results of a case-control study. J Am Acad Dermatol. 2015;73(4):604–608. doi: 10.1016/j.jaad.2015.07.009

[2] Rainer B.M., Fischer A.H., Luz Felipe da Silva D., et al. Rosacea is associated with chronic systemic diseases in a skin severity-dependent manner: results of a case-control study // J Am Acad Dermatol. 2015. Vol. 73, N 4. Р. 604–608. doi: 10.1016/j.jaad.2015.07.009

[3] Weinkle AP, Doktor V, Emer J. Update on the management of rosacea. Plast Surg Nurs. 2015;35(4):184–202. doi: 10.1097/PSN.0000000000000111

[4] Weinkle A.P., Doktor V., Emer J. Update on the management of rosacea // Plast Surg Nurs. 2015. Vol. 35, N 4. Р. 184–202. doi: 10.1097/PSN.0000000000000111

[5] Chen W, Plewig G. Human demodicosis: revisit and a proposed classification. Br J Dermatol. 2014;170(6):1219–1225. doi: 10.1111/bjd.12850

[6] Chen W., Plewig G. Human demodicosis: revisit and a proposed classification // Br J Dermatol. 2014. Vol. 170, N 6. Р. 1219–1225. doi: 10.1111/bjd.12850

[7] Samodelkina KA, Korotkiy NG, Mayatskaya TV. Modern concepts of etiology and pathogenesis of rosacea. Clinical Dermatology and Venereology. 2012;10(3):4–8. (In Russ).

[8] Самоделкина К.А., Короткий Н.Г., Маяцкая Т.В. Современные концепции этиологии и патогенеза розацеа // Клиническая дерматология и венерология. 2012. Т. 10, № 3. С. 4–8.

[9] Khamaganova IV, Ikonnikova NA, Galkina OA. Trichopol in complex therapy of rosacea. Con med. Application. Dermatology. 2005. Р. 22–25. (In Russ).

[10] Хамаганова И.В., Иконникова Н.А., Галкина О.А. Трихопол в комплексной терапии розацеа // Con med. Приложение. Дерматология. 2005. С. 22–25.

[11] Abram K, Silm H, Maaroos HI, Oona M. Risk factors associated with rosacea. J Eur Acad Dermatol Venereol. 2010;24(5):565–571. doi: 10.1111/j.1468-3083.2009.03472.x

[12] Abram K., Silm H., Maaroos H.I., Oona M. Risk factors associated with rosacea // J Eur Acad Dermatol Venereol. 2010. Vol. 24, N 5. P. 565–571. doi: 10.1111/j.1468-3083.2009.03472.x

[13] Rice WG, Weiss SJ. Regulation of proteolysis at the neutrophilsubstrate interface by secretory leukoprotease inhibitor. Science. 1990;249(4965):178–181. doi: 10.1126/science.2371565

[14] Rice W.G., Weiss S.J. Regulation of proteolysis at the neutrophilsubstrate interface by secretory leukoprotease inhibitor // Science. 1990. Vol. 249, N 4965. Р. 178–181. doi: 10.1126/science.2371565

[15] Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venereol. 1989;69(5):419–423.

[16] Berg M., Liden S. An epidemiological study of rosacea // Acta Derm Venereol. 1989. Vol. 69, N 5. Р. 419–423.

[17] Chang AL, Raber I, Xu J, et al. Assessment of the genetic basis of rosacea by genome-wide association study. J Invest Dermatol. 2015;135(6):1548–1555. doi: 10.1038/jid.2015.53

[18] Chang A.L., Raber I., Xu J. et al. Assessment of the genetic basis of rosacea by genome-wide association study // J Invest Dermatol. 2015. Vol. 135, N 6. Р. 1548–1555. doi: 10.1038/jid.2015.53

[19] Chosidow O, Cribier B. Epidemiology of rosacea: updated data. Ann Dermatol Venereol. 2011;138(Suppl 3):179–183. doi: 10.1016/S0151-9638(11)70087-4

[20] Chosidow O., Cribier B. Epidemiology of rosacea: updated data // Ann Dermatol Venereol. 2011. Vol. 138, Suppl 3. Р. 179–183. doi: 10.1016/S0151-9638(11)70087-4

[21] Michel JL, Cabibel F. Frequency, severity and treatment of ocular rosacea during cutaneous rosacea. Ann Dermatol Venereol. 2003;130(1 Pt 1):20–24.

[22] Michel J.L., Cabibel F. Frequency, severity and treatment of ocular rosacea during cutaneous rosacea // Ann Dermatol Venereol. 2003. Vol. 130, N 1, Pt 1. Р. 20–24.

[23] Spoendlin J, Voegel JJ, Jick SS, Meier CR. A study on the epidemiology of rosacea in the U.K. Br J Dermatol. 2012;167(3):598–605. doi: 10.1111/j.1365-2133.2012.11037.x

[24] Spoendlin J., Voegel J.J., Jick S.S., Meier C.R. A study on the epidemiology of rosacea in the U.K. // Br J Dermatol. 2012. Vol. 167, N 3. Р. 598–605. doi: 10.1111/j.1365-2133.2012.11037.x

[25] Olisova OY, Kochergin NG, Smirnova EA. Modern external therapy of moderate forms of rosacea. Russian Journal of Skin and Venereal Diseases. 2016;19(6):328–334. (In Russ).

[26] Олисова О.Ю., Кочергин Н.Г., Смирнова Е.А. Современная наружная терапия среднетяжелых форм розацеа // Российский журнал кожных и венерических болезней. 2016. Т. 19, № 6. С. 328–334.

[27] Ramelet AA. Rosacea: a reaction pattern associated with ocular lesions and migraine? Arch Dermatol. 1994;130(11):1448. doi: 10.1001/archderm.1994.01690110118022

[28] Ramelet A.A. Rosacea: a reaction pattern associated with ocular lesions and migraine? // Arch Dermatol. 1994. Vol. 130, N 11. Р. 1448. doi: 10.1001/archderm.1994.01690110118022

[29] Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the national rosacea society expert committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46(4):584–587. doi: 10.1067/mjd.2002.120625

[30] Wilkin J., Dahl M., Detmar M., et al. Standard classification of rosacea: report of the national rosacea society expert committee on the classification and staging of rosacea // J Am Acad Dermatol. 2002. Vol. 46, N 4. Р. 584–587. doi: 10.1067/mjd.2002.120625

[31] Guzman-Sanchez DA, Ishiuji Y, Patel T, et al. Enhanced skin blood flow and sensitivity to noxious heat stimuli in papulopustular rosacea. J Am Acad Dermatol. 2007;57(5):800–805. doi: 10.1016/j.jaad.2007.06.009

[32] Guzman-Sanchez D.A., Ishiuji Y., Patel T., et al. Enhanced skin blood flow and sensitivity to noxious heat stimuli in papulopustular rosacea // J Am Acad Dermatol. 2007. Vol. 57, N 5. Р. 800–805. doi: 10.1016/j.jaad.2007.06.009

[33] Sibenge S, Gawkrodger DJ. Rosacea: a study of clinical patterns, blood flow, and the role of Demodex folliculorum. J Am Acad Dermatol. 1992;26(4):590–593. doi: 10.1016/0190-9622(92)70086-u

[34] Sibenge S., Gawkrodger D.J. Rosacea: a study of clinical patterns, blood flow, and the role of Demodex folliculorum // J Am Acad Dermatol. 1992. Vol. 26, N 4. Р. 590–593. doi: 10.1016/0190-9622(92)70086-u

[35] Del Rosso JQ, Baldwin H, Webster G, et al. American Acne & Rosacea Society rosacea medical management guidelines. J Drugs Dermatol. 2008;7(6):531–533.

[36] Del Rosso J.Q., Baldwin H., Webster G., et al. American Acne & Rosacea Society rosacea medical management guidelines // J Drugs Dermatol. 2008. Vol. 7, N 6. Р. 531–533.

[37] Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis. 2013;92(6):277–284.

[38] Del Rosso J.Q., Thiboutot D., Gallo R., et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents // Cutis. 2013. Vol. 92, N 6. Р. 277–284.

[39] Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol. 2013;69(6 Suppl 1):27–35. doi: 10.1016/j.jaad.2013.04.043

[40] Tan J., Berg M. Rosacea: current state of epidemiology // J Am Acad Dermatol. 2013. Vol. 69, N 6, Suppl 1. Р. 27–35. doi: 10.1016/j.jaad.2013.04.043

[41] Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51(3):327–341. doi: 10.1016/j.jaad.2004.03.030

[42] Crawford G.H., Pelle M.T., James W.D. Rosacea: I. Etiology, pathogenesis, and subtype classification // J Am Acad Dermatol. 2004. Vol. 51, N 3. Р. 327–341. doi: 10.1016/j.jaad.2004.03.030

[43] Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-infl ammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791–802. doi: 10.1016/j.jaad.2006.11.021

[44] Del Rosso J.Q., Webster G.F., Jackson M., et al. Two randomized phase III clinical trials evaluating anti-infl ammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea // J Am Acad Dermatol. 2007. Vol. 56, N 5. Р. 791–802. doi: 10.1016/j.jaad.2006.11.021

[45] Fowler J, Jackson M, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12(6):650–656.

[46] Fowler J., Jackson M., Moore A., et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies // J Drugs Dermatol. 2013. Vol. 12, N 6. Р. 650–656.

[47] Zouboulis CC. The skin as an endocrine organ. Dermatoendocrinol. 2009;1(5):250–252. doi: 10.4161/derm.1.5.9499

[48] Zouboulis C.C. The skin as an endocrine organ // Dermatoendocrinol. 2009. Vol. 1, N 5. Р. 250–252. doi: 10.4161/derm.1.5.9499

[49] Wilkin JK. Oral thermal-induced flushing in erythematotelangiectatic rosacea. J Invest Derm. 1981;76(1):15–18. doi: 10.1111/1523-1747.ep12524458

[50] Wilkin J.K. Oral thermal-induced flushing in erythematotelangiectatic rosacea // J Invest Derm. 1981. Vol. 76, N 1. Р. 15–18. doi: 10.1111/1523-1747.ep12524458

[51] West JB, Mathieu-Costello O. Stress failure of pulmonary capillaries: role in lung and heart disease. Lancet. 1992;340(8822):762–767. doi: 10.1016/0140-6736(92)92301-u

[52] West J.B., Mathieu-Costello O. Stress failure of pulmonary capillaries: role in lung and heart disease // Lancet. 1992. Vol. 340, N 8822. Р. 762–767. doi: 10.1016/0140-6736(92)92301-u

[53] Motley RJ, Barton S, Marks R. The signifi cance of telangiectasia in rosacea. In: Acne and Related Disorders: An International Symposium. Wales: Martin Dunitz: Cardiff; 1989. Р. 339–344.

[54] Motley R.J., Barton S., Marks R. The signifi cance of telangiectasia in rosacea // Acne and Related Disorders: An International Symposium. Wales: Martin Dunitz: Cardiff, 1989. Р. 339–344.

[55] Olisova OY, Dodina MI, Kushlinskiy NE. The role of vascular endothelial growth factor in rosacea pathogenesis and it’s medical correction. Russian Journal of Clinical Dermatology and Venereology. 2012;10(1):49–55. (In Russ).

[56] Олисова О.Ю., Додина М.И., Кушлинский Н.Е. Роль фактора роста сосудистого эндотелия в патогенезе розацеа и его медикаментозная коррекция // Клиническая дерматология и венерология. 2012. Т. 10, № 1. С. 49–55.

[57] Dermatovenerology. Ed. by Y.S. Butova, O.K. Skripkina, O.L. Ivanova. Moscow: GEOTAR-Media; 2013. 896 p. (In Russ).

[58] Дерматовенерология / под ред. Ю.С. Бутова, О.К. Скрипкина, О.Л. Иванова. Москва: ГЭОТАР-Медиа, 2013. 896 с.

[59] Katkhanova OA, Stenin AV. Complex therapy of acneform dermatoses. Experimental and Clinical Dermatocosmetology. 2014;(2):1–6. (In Russ).

[60] Катханова О.А., Стенин А.В. Комплексная терапия акнеформных дерматозов // Экспериментальная и клиническая дерматокосметология. 2014. № 2. С. 1–6.

[61] Svirshchevskaya EV, Matushevskaya EV, Matushevskaya YI. Actual issues of pathogenesis and therapy of rosacea. Clinical Dermatology and Venereology. 2017;16(4):4–12. (In Russ). doi: 10.17116/klinderma20171644-13

[62] Свирщевская Е.В., Матушевская Е.В., Матушевская Ю.И. Актуальные вопросы патогенеаза и терапии розацеа // Клиническая дерматология и венерология. 2017. Т. 16, № 4. С. 4–12. doi: 10.17116/klinderma20171644-13

[63] Zuuren EJ, Graber MA, Hollis S, et al. Interventions for rosacea. Cochrane Database Syst Res. 2005;(3):CD003262. doi: 10.1002/14651858.CD003262.pub3

[64] Zuuren E.J., Graber M.A., Hollis S., et al. Interventions for rosacea // Cochrane Database Syst Res. 2005. N 3. CD003262. doi: 10.1002/14651858.CD003262.pub3

[65] Borovaya A, Olisova O, Ruzicka T, Sardy M. Does isotretinoin therapy of acne cure or cause depression? Int J Dermatology. 2013;52(9):1040–1052. doi: 10.1111/ijd.12169

[66] Borovaya A., Olisova O., Ruzicka T., Sardy M. Does isotretinoin therapy of acne cure or cause depression? // Int J Dermatology. 2013. Vol. 52, N 9. Р. 1040–1052. doi: 10.1111/ijd.12169

[67] Pankina ES. Violations of microcirculation of the skin of the face with rosacea and methods of their correction [dissertation abstract]. Saint Petersburg; 2008. 20 р. (In Russ).

[68] Панкина Е.С. Нарушения микроциркуляции кожи лица при розацеа и методы их коррекции: Автореф. дис. ... канд. мед. наук. Санкт-Петербург, 2008. 20 с.

[69] Elewski BE, Draelos Z, Dréno B, et al. Rosacea ― global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol. 2011;25(2):188–200. doi: 10.1111/j.1468-3083.2010.03751.x

[70] Elewski B.E., Draelos Z., Dréno B., et al. Rosacea ― global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group // J Eur Acad Dermatol Venereol. 2011. Vol. 25, N 2. Р. 188–200. doi: 10.1111/j.1468-3083.2010.03751.x

[71] Draelos ZD. Cosmetics in acne and rosacea. Semin Cutan Med Surg. 2001;20(3):209–214. doi: 10.1053/sder.2001.27556

[72] Draelos Z.D. Cosmetics in acne and rosacea // Semin Cutan Med Surg. 2001. Vol. 20, N 3. Р. 209–214. doi: 10.1053/sder.2001.27556

[73] Babilas P, Schreml S, Szeimies RM, et al. Intense pulsed light (IPL): a review. Lasers Surg Med. 2010;42(2):93–104. doi: 10.1002/lsm.20877

[74] Babilas P., Schreml S., Szeimies R.M., et al. Intense pulsed light (IPL): a review // Lasers Surg Med. 2010. Vol. 42, N 2. Р. 93–104. doi: 10.1002/lsm.20877

[75] Chen Y, Moore CD, Zhang JY, et al. TRPV4 moves toward center-fold in rosacea pathogenesis. J Invest Dermatol. 2017;137(4):801–804. doi: 10.1016/j.jid.2016.12.013

[76] Chen Y., Moore C.D., Zhang J.Y., et al. TRPV4 moves toward center-fold in rosacea pathogenesis // J Invest Dermatol. 2017. Vol. 137, N 4. Р. 801–804. doi: 10.1016/j.jid.2016.12.013

[77] Dorofeeva TG, Komarovsky VS. Technologies based on light, radio frequency and plasma effects in aesthetic medicine. Almanac of CLinical Medicine. 2008;(17-2):184–185. (In Russ).

[78] Дорофеева Т.Г., Скомаровский В.С. Технологии на основе световых, радиочастотных и плазменных воздействий в эстетической медицине // Альманах клинической медицины. 2008. № 17-2. С. 184–185.

[79] Schoenewolf NL, Barysch MJ, Dummer R. Basics in dermatological laser applications. In: Current problems in dermatology. Editors: Bogdan-Allemann I, Goldberg DJ. Basel: Karger; 2011. Р. 42.

[80] Schoenewolf N.L., Barysch M.J., Dummer R. Basics in dermatological laser applications // Current problems in dermatology. Editors: Bogdan-Allemann I., Goldberg D.J. Basel: Karger, 2011. Р. 42.

[81] Kovalchuk LA, Goncharuk VY. Experience of treatment of patients with rosacea. Innovative technologies in the diagnosis and treatment of skin diseases and infections of the urogenital tract. In: Abstracts of the regional scientific and practical conference with international participation. Grodno; 2012. Р. 64–67. (In Russ).

[82] Ковальчук Л.А., Гончарук В.Ю. Опыт лечения больных розацеа. Инновационные технологии в диагностике и лечении кожных заболеваний и инфекций урогенитального тракта // Тезисы региональной научно-практической конференции с международным участием. Гродно, 2012. С. 64–67.

[83] Gao L, Gao N, Song W, et al. A retrospective study on efficacy of pulsed dye laser and intense pulsed light for the treatment of facial telangiectasia. J Drugs Dermatol. 2017;16(11):1112–1116.

[84] Gao L., Gao N., Song W., et al. A retrospective study on efficacy of pulsed dye laser and intense pulsed light for the treatment of facial telangiectasia // J Drugs Dermatol. 2017. Vol. 16, N 11. Р. 1112–1116.

[85] Kruglova LS, Kotenko KV, Orlova EN. Laser therapy and ultrasound therapy in the treatment of patients with rosacea. Bulletin of New Medical Technologies. 2014;(1):96. (In Russ).

[86] Круглова Л.С., Котенко К.В., Орлова Е.Н. Лазеротерапия и ультразвуковая терапия в лечении больных розацеа // Вестник новых медицинских технологий. 2014. № 1. С. 96.

[87] Papageorgiou P, Clayton W, Norwood S, et al. Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results. Br J Dermatol. 2008;159(3):628–632. doi: 10.1111/j.1365-2133.2008.08702.x

[88] Papageorgiou P., Clayton W., Norwood S., et al. Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results // Br J Dermatol. 2008. Vol. 159, N 3. Р. 628–632. doi: 10.1111/j.1365-2133.2008.08702.x

[89] Kenneth AM, Sparacio MR, Voigt A, Objective and quantitative improvement of rosacea-associated erythema after intense pulsed light treatment. Dermatol Surg. 2003;29(6):600–604. doi: 10.1046/j.1524-4725.2003.29141.x

[90] Kenneth A.M., Sparacio M.R., Voigt A. Objective and quantitative improvement of rosacea-associated erythema after intense pulsed light treatment // Dermatol Surg. 2003. Vol. 29, N 6. Р. 600–604. doi: 10.1046/j.1524-4725.2003.29141.x

RIGHTS & PERMISSIONS

Eco-Vector